Interestingly, an exploratory study by Horiike and colleagues determined that NSCLC patients do not exhibit response to sorafenib (136), suggesting that RET fusion-positive NSCLC patients may not gain clinical benefit from this compound, though this requires additional testing in RET-altered NSCLC patients and other RET-altered cancers. The gene discussed is RET; the disease is cancer.